Tevogen Bio Holdings Inc. Receives Nasdaq Delisting Notice: Key Details for Investors

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced that on April 16, 2026, it received a letter from the Nasdaq Listing Qualifications Staff notifying the Company of its failure to satisfy certain continued listing requirements for the Nasdaq Global Market. This development is significant for shareholders, as it may have a material impact on the Company’s share price and future trading status.

Key Points from the Report

• Nasdaq Non-Compliance Notice: Tevogen Bio Holdings Inc. was notified by Nasdaq that it failed to meet specific continued listing standards related to market value.
• Market Value Requirements: The letter specifically addressed deficiencies in:
  • Market Value of Listed Securities (MVLS): The Company’s market value of listed securities fell below the \$50 million minimum required for continued listing on the Nasdaq Global Market.
  • Market Value of Publicly Held Shares (MVPHS): The Company’s market value of publicly held shares was also below the \$15 million threshold required.
• Compliance Timeline: Nasdaq has granted Tevogen a period of 180 calendar days to regain compliance:
  • MVLS Compliance Date: October 13, 2026
  • MVPHS Compliance Date: October 14, 2026
• Path to Compliance: If at any time before the applicable deadlines the Company’s market value of listed securities closes at \$50 million or more, or its market value of publicly held shares closes at \$15 million or more for a minimum of 10 consecutive business days (and generally not more than 20 consecutive business days), Nasdaq will provide written notification that compliance has been regained.
• Potential Actions: The Company stated it intends to actively monitor its market value metrics and may consider available options to regain compliance, including applying for a transfer to The Nasdaq Capital Market. However, there is no assurance that the Company will take any specific action or succeed in regaining compliance.
• Current Status:
  • The Company remains listed on the Nasdaq Global Market for now, but continued listing is at risk if compliance is not restored.
  • Tevogen Bio is designated as an “Emerging Growth Company.”
  • The Company’s listed securities are:
    • Common Stock, par value \$0.0001 per share (Trading Symbol: TVGN)
    • Warrants, exercisable for \$575 per share of Common Stock (Trading Symbol: TVGNW)
    • Both securities are registered and currently trade on the Nasdaq Stock Market LLC.

Price-Sensitive and Shareholder-Relevant Information

• Risk of Delisting: If Tevogen fails to regain compliance with Nasdaq’s MVLS and MVPHS requirements, its shares and warrants could be delisted from Nasdaq. This would likely have a negative impact on share liquidity, trading volume, and price.
• Uncertainty and Volatility: The Company’s indication that there is “no assurance” it will succeed in regaining compliance introduces significant uncertainty, which may increase share price volatility.
• Potential Corporate Actions: While management may consider actions such as applying for a transfer to the Nasdaq Capital Market, such moves may not prevent delisting if compliance cannot be achieved.
• Investor Monitoring Needed: Shareholders should monitor further announcements from Tevogen regarding its compliance plan and any material changes to its listing status.

What Should Investors Do?

Investors in Tevogen Bio Holdings Inc. should be aware that the Company is at risk of being delisted from the Nasdaq Global Market if it does not regain compliance with the market value requirements by the stated deadlines. Delisting would affect the trading of TVGN and TVGNW securities, potentially causing a decline in value and reduced liquidity.

Management has not yet announced any specific measures to address the deficiency but is evaluating options. Investors are advised to stay alert to future communications from the Company and exercise caution during this period of uncertainty.

Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The information provided is based on public filings and may be subject to change or updates. The author and publisher do not hold any responsibility for investment actions taken based on this article.

View Tevogen Bio Holdings Inc. Historical chart here